includes:study
Are GLP1 side effects all the same?
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
includes:study
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
category:news
23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.
includes:review
Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.
drug:amycretin
Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
category:news
What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.
categeory:watercooler
Wondering what the world was doing before GLP1s? We discuss Topiramate, a popular appetite suppressant.
category:news
Is mimicking more hormones better? Let's find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist
category:news
Are GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc) primarily brain drugs?
company:eli-lilly
As the race to manufacture more GLP1 medications intensifies, Eli Lilly gets approval in China and more suppliers.
chemical:semaglutide
Can we trust research funded by Novo Nordisk which found a 24% decrease in kidney disease risk for people on Semaglutide (Ozempic)?
categeory:watercooler
We dive deep into the reports of people's GLP1 costs -- how much is the average person paying for Ozempic, Wegovy, Mounjaro, Zepbound and others?
drug:danuglipron
Read more about Dangulipron, Pfizer's GLP1 receptor agonist. Will it be better than Ozempic, Wegovy, Mounjaro, Zepbound and others?